Recruiting
Dato-DXd
Phase 3 Lung Cancer
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Trial #: NCT05555732
Recruiting
T-DXd
Breast Cancer
DESTINY Breast Respond HER2-low Europe
Trial #: NCT05945732
Recruiting
T-DXd
Gastric Cancer
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
Trial #: NCT05993234
Not yet recruiting
T-DXd
Phase 3 Gynecologic Cancers
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Trial #: NCT07022483
Recruiting
Other/Multi
Lung Cancer
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Trial #: NCT04165798
Recruiting
T-DXd
Lung Cancer
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Trial #: NCT06809764
Recruiting
T-DXd
Phase 3 Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Trial #: NCT06899126
Recruiting
I-DXd
Phase 1 Phase 2 Lung Cancer
A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Trial #: NCT04471727
Recruiting
T-DXd
Phase 3 Tumor-agnostic
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Trial #: NCT06174987
Recruiting
T-DXd
Phase 2 Gastric Cancer
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Trial #: NCT04379596
Pages: 1  2  3  4  5  6  7  

The content contained is taken is taken directly from public registry ClinicalTrials.gov and has not been edited.

Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.